Terns Pharmaceuticals Inc.
Terns Pharmaceuticals Announces Positive Phase 1 Data for TERN-701 at ASH 2025
Summary
Terns Pharmaceuticals, Inc. announced updated and expanded Phase 1 clinical data for TERN-701, its novel investigational allosteric BCR::ABL1 inhibitor, at the 67th American Society of Hematology (ASH) Annual Meeting on December 8, 2025. The data demonstrated high molecular response rates in patients with previously treated chronic myeloid leukemia (CML). TERN-701 achieved a 74% major molecular response (MMR) rate by 24 weeks in efficacy-evaluable patients and 80% MMR rate in patients at doses ≥ 320mg QD, with a favorable safety profile. The company has selected 320mg and 500mg QD as the recommended phase 2 doses for expansion. The ongoing CARDINAL trial has enrolled over 85 patients. The results reinforce TERN-701's potential as a best-in-disease therapy in CML treatment settings.
Profitelligence Alerts
Get alerts for TERN
Be first to know when Terns Pharmaceuticals Inc. files with the SEC.
Filing Categories
Advertisement
About Terns Pharmaceuticals Inc.
Terns Pharmaceuticals Inc. is a biopharmaceutical company dedicated to the discovery and development of novel therapeutic candidates targeting liver disease and oncology. Its primary function is to advance its pipeline of clinical and preclinical drug candidates that address significant unmet medical needs. One of the company's main focuses is on non-alcoholic steatohepatitis (NASH), a progressive liver disease. Through innovative approaches, Terns Pharmaceuticals explores various mechanisms to treat NASH, including small molecules designed to reduce liver inflammation and fibrosis. Beyond liver disease, the company is expanding its platform to include oncology, diversifying its impact in the healthcare industry. As a key player in the biopharmaceutical sector, Terns Pharmaceuticals Inc. contributes to the growing landscape of targeted therapies. With a dedicated emphasis on research and development, the company plays an essential role in pushing the boundaries of treatment options, potentially transforming the management of chronic liver diseases and cancer.
Official SEC Documents
Advertisement